Inhibition of Ras for cancer treatment: the search continues

Activation and Involvement of Ral GTPases in Colorectal Cancer

(2011) T. D. Martin et al.   CANCER RESEARCH

STK33 Kinase Activity Is Nonessential in KRAS-Dependent Cancer Cells

(2011) C. Babij et al.   CANCER RESEARCH

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

TLN-4601, a novel anticancer agent, inhibits Ras signaling post Ras prenylation and before MEK activation

(2010) Nadia Boufaied et al.   ANTI-CANCER DRUGS

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

(2010) Sonja J. Heidorn et al.   CELL

Salirasib in the treatment of pancreatic cancer

(2010) Ernesto Bustinza-Linares et al.   Future Oncology

Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma

(2010) Ghassan K. Abou-Alfa et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Aberrant Overexpression of the Rgl2 Ral Small GTPase-specific Guanine Nucleotide Exchange Factor Promotes Pancreatic Cancer Growth through Ral-dependent and Ral-independent Mechanisms

(2010) Dominico Vigil et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Inactivating GGTase-I reduces disease phenotypes in a mouse model of K-RAS-induced myeloproliferative disease

(2010) A-K M Sjogren et al.   LEUKEMIA

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

(2010) Gideon Bollag et al.   NATURE

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

(2010) Cory M. Johannessen et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer

(2010) M. Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Posttranslational Processing of Prelamin A and Disease

(2009) Brandon S.J. Davies et al.   Annual Review of Genomics and Human Genetics

A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival

(2009) Anurag Singh et al.   CANCER CELL

Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells

(2009) Claudia Scholl et al.   CELL

A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene

(2009) Ji Luo et al.   CELL

In vitro and In vivo Radiosensitization with AZD6244 (ARRY-142886), an Inhibitor of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase 1/2 Kinase

(2009) E. J. Chung et al.   CLINICAL CANCER RESEARCH

Targeting the PI3K signaling pathway in cancer

(2009) Kwok-Kin Wong et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Lack of KRAS and BRAF Mutation in Renal Cell Carcinoma

(2009) S. Gattenlöhner et al.   EUROPEAN UROLOGY

Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines

(2009) Kathryn Balmanno et al.   INTERNATIONAL JOURNAL OF CANCER

Aurora-A Phosphorylates, Activates, and Relocalizes the Small GTPase RalA

(2009) K.-H. Lim et al.   MOLECULAR AND CELLULAR BIOLOGY

Palmitoyl acyltransferase assays and inhibitors (Review)

(2009) Jeremiah M. Draper et al.   MOLECULAR MEMBRANE BIOLOGY

Ras/MAPK signaling from endomembranes

(2009) Nicole Fehrenbacher et al.   Molecular Oncology

A dimerization-dependent mechanism drives RAF catalytic activation

(2009) Thanashan Rajakulendran et al.   NATURE

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

(2009) David A. Barbie et al.   NATURE

Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling

(2009) A B Hanker et al.   ONCOGENE

V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

(2009) C. A. Pratilas et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Synthetic lethality: a framework for the development of wiser cancer therapeutics

(2009) William G Kaelin   Genome Medicine

Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease

(2008) A. M. Wahlstrom et al.   BLOOD

Effect of Rapamycin Alone and in Combination with Sorafenib in an Orthotopic Model of Human Hepatocellular Carcinoma

(2008) Z. Wang et al.   CLINICAL CANCER RESEARCH

mTOR inhibitors in the treatment of cancer

(2008) Angelica Fasolo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

A Small Molecule Inhibitor of Isoprenylcysteine Carboxymethyltransferase Induces Autophagic Cell Death in PC3 Prostate Cancer Cells

(2008) Mei Wang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers

(2008) Alex A. Adjei et al.   JOURNAL OF CLINICAL ONCOLOGY

Aplysamine 6, an Alkaloidal Inhibitor of Isoprenylcysteine Carboxyl Methyltransferase from the SpongePseudoceratinasp.

(2008) Malcolm S. Buchanan et al.   JOURNAL OF NATURAL PRODUCTS

BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells

(2008) E. Sala et al.   MOLECULAR CANCER RESEARCH

Somatic mutations affect key pathways in lung adenocarcinoma

(2008) Li Ding et al.   NATURE

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE

Ras oncogenes: split personalities

(2008) Antoine E. Karnoub et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Drug discovery approaches targeting the PI3K/Akt pathway in cancer

(2008) C Garcia-Echeverria et al.   ONCOGENE

Small-molecule inhibitors of the cancer target, isoprenylcysteine carboxyl methyltransferase, from Hovea parvicalyx

(2008) Malcolm S. Buchanan et al.   PHYTOCHEMISTRY

Inhibitors of Chronically Active Ras: Potential for Treatment of Human Malignancies

(2008) Yoel Kloog et al.   Recent Patents on Anti-Cancer Drug Discovery

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

(2008) S. Jones et al.   SCIENCE